Antagonists of Myelin-associated Glycoprotein and their use in the treatment and/or prevention of Neurological diseases

The use of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof in the preparation of a medicament for treatment or prophylaxis of stroke and other neurological diseases.

A method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease which comprises administering to said human in need thereof an effective amount of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof.

The use of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof in the preparation of a medicament for inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering from, or at risk of developing, a stroke and other neurological disease.

An altered anti-MAG antibody and functional fragments thereof.

An altered anti-MAG antibody or functional fragment thereof which comprises:

• a) an antibody light chain variable domain comprising a light chain of an acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the light chain of a non-human donor monoclonal antibody that specifically binds to MAG and/or
• b) an antibody heavy chain variable domain comprising a heavy chain of an acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the heavy chain of a non-human donor monoclonal antibody that specifically binds to MAG.

A pharmaceutical composition comprising an antibody according to any of claims 5-12 or a functional fragment thereof together with a pharmaceutically acceptable carrier.